Maimonides Institute for Biomedical Research of Córdoba, Córdoba, Spain.
Department of Cell Biology, Physiology and Immunology, University of Córdoba, Córdoba, Spain.
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3389-3402. doi: 10.1210/jc.2019-00021.
Nonalcoholic fatty liver disease (NAFLD) is a common obesity-associated pathology characterized by hepatic fat accumulation, which can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. Obesity is associated with profound changes in gene-expression patterns of the liver, which could contribute to the onset of comorbidities.
As these alterations might be linked to a dysregulation of the splicing process, we aimed to determine whether the dysregulation in the expression of splicing machinery components could be associated with NAFLD.
We collected 41 liver biopsies from nonalcoholic individuals with obesity, with or without hepatic steatosis, who underwent bariatric surgery.
The expression pattern of splicing machinery components was determined using a microfluidic quantitative PCR-based array. An in vitro approximation to determine lipid accumulation using HepG2 cells was also implemented.
The liver of patients with obesity and steatosis exhibited a severe dysregulation of certain splicing machinery components compared with patients with obesity without steatosis. Nonsupervised clustering analysis allowed the identification of three molecular phenotypes of NAFLD with a unique fingerprint of alterations in splicing machinery components, which also presented distinctive hepatic and clinical-metabolic alterations and a differential response to bariatric surgery after 1 year. In addition, in vitro silencing of certain splicing machinery components (i.e., PTBP1, RBM45, SND1) reduced fat accumulation and modulated the expression of key de novo lipogenesis enzymes, whereas conversely, fat accumulation did not alter spliceosome components expression.
There is a close relationship between splicing machinery dysregulation and NAFLD development, which should be further investigated to identify alternative therapeutic targets.
非酒精性脂肪性肝病(NAFLD)是一种常见的肥胖相关病理,其特征为肝脂肪堆积,可进展为纤维化、肝硬化和肝细胞癌。肥胖与肝脏基因表达模式的深刻变化有关,这些变化可能导致合并症的发生。
由于这些改变可能与剪接过程的失调有关,我们旨在确定剪接机制成分表达的失调是否与 NAFLD 有关。
我们收集了 41 例因肥胖而行减重手术的非酒精性个体的肝活检组织,这些个体中有的存在肝脂肪变性,有的不存在。
使用基于微流控定量 PCR 的阵列确定剪接机制成分的表达模式。还实施了一种体外近似方法来确定 HepG2 细胞中的脂质积累。
与肥胖但无脂肪变性的患者相比,肥胖伴脂肪变性的患者肝脏中某些剪接机制成分严重失调。无监督聚类分析允许鉴定出三种具有独特剪接机制成分改变特征的 NAFLD 分子表型,这些表型还表现出独特的肝和临床代谢改变,以及减重手术后 1 年的反应存在差异。此外,某些剪接机制成分(如 PTBP1、RBM45、SND1)的体外沉默减少了脂肪积累,并调节了从头合成脂肪的关键酶的表达,而相反,脂肪积累不会改变剪接体成分的表达。
剪接机制失调与 NAFLD 的发生密切相关,应进一步研究以确定替代治疗靶点。